Status:
UNKNOWN
3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH
Lead Sponsor:
Regina Steringer-Mascherbauer
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to document the left and right ventricular function in patients with sclerodermia associated pulmonal arterial hypertension via 3D echocardiography. The results of this study s...
Detailed Description
The 3D echocardiography could provide early and detailed information about the changes in the left and right ventricle. The prediction of sclerodermia associated pulmonary arterial hypertension (PAH)...
Eligibility Criteria
Inclusion
- age \>17
- pulmonary arterial hypertension (PAH) associated with WHO group 1 who start a parenteral prostanoid-therapy
- written informed consent
- prostanoid naive
- no change of the PAH specific therapy within 3 weeks of the recruitment to the study
Exclusion
- pregnancy and lactation period
- Women of child bearing potential who do not use an effective and secure method for birth control
- severe chronic kidney insufficiency (glomerular filtration rate \<30), which will remain for more than 3 months
- liver-insufficiency Child C
- life expectancy shorter than the course of the study (for example because of malignant disease
Key Trial Info
Start Date :
June 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT02207868
Start Date
June 1 2014
End Date
December 1 2019
Last Update
May 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Krankenhaus der Elisabethinen Linz GmbH
Linz, Upper Austria, Austria, 4020